A Phase 1 interventional study of Nivolumab and Relatlimab in Hepatocellular Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 1, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing nivolumab in Carcinoma, Hepatocellular — 11 open to participants now, 17 under way, 1 of them phase 3. Nivolumab · Carcinoma, Hepatocellular.
Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, this one is the 32nd largest by enrollment, is one of 5 that started in 2021, is one of 12 in phase 1, reaches primary completion later than 3 of the 16 other live ones, and was the 37th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →11 of the 53 studies testing nivolumab in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Hawaii · Sites in United States
Ages 18+
West China Hospital · Sites in China
Ages 18–80
Diwakar Davar · Sites in United States
Ages 18+
National University Hospital, Singapore · Sites in Singapore
Ages 21–99
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 36 · Phase 3 6
First in 2012; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 40 across the 53 interventional studies. Of the 32 that completed or were terminated, 10 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 53 have an industry lead sponsor. The 10 most frequent:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is the lead sponsor of 582 studies on the registry; 71 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 68 (60%) have results posted.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins has 8 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
5 of the studies testing nivolumab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04472767University of California, IrvineCabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | 2027-01-31 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
| NCT07919717Shanghai Zhongshan HospitalNIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC | 2027-05-12 |
| NCT07075120University of HawaiiIpilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | 2027-08-01 |
| NCT05475613Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityDownstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and feasibility of neoadjuvant/adjuvant Nivolumab or Nivolumab plus Relatlimab in patients with HCC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Technically resectable HCC as defined by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive Nivolumab only.
Drug: Nivolumab
Participants receive Nivolumab and Relatlimab.
Drug: Nivolumab · Drug: Relatlimab
Patients received 480mg Nivolumab as a 30 minute IV infusion on Day 1 of Cycles 1 and 2 (28 day cycles) prior to surgery. Post-surgery, patients received an additional 10 doses of adjuvant 480mg Nivolumab therapy on Day 1 of each cycle (every 28 days).
Also known as: OPDIVO™, BMS 936558, MDX1106, ONO-4538
Patients received either 480mg or 960mg Relatlimab as a 30 minute IV infusion on Day 1 of Cycles 1 and 2 (28 day cycles) prior to surgery. Post-surgery, patients received an additional 10 doses of adjuvant 480mg or 960mg Relatlimab therapy on Day 1 every 28 days. Dosing was changed from 960mg to 480mg based on guidance from Bristol Myers Squibb.
Also known as: BMS-986016, BMS-986016-01, Anti-LAG-3
Number of Patients Precluded From Surgery
Number of patients that experienced a treatment-related adverse event that precludes continuing on to surgery within 60 days of the last dose of neoadjuvant treatment. Individuals who do not go on to receive surgery due to other causes (e.g. progressive disease, patient refusal) will not be counted as feasibility failures.
Time frame: Up to 2 months
Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Event (AE)
When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject.
Time frame: Up to 15 months
Number of Participants Who Obtain R0 Resection
Number of evaluable participants who obtain R0 resection. R0 resection rate will be estimated among the patients who receive at least one dose of neoadjuvant treatment and went to surgery. R0 resection is defined by a microscopically margin-negative resection, in which no tumor (gross or microscopic) remains in the primary tumor bed.
Time frame: Up to 2 months
Number of Evaluable Patients With Pathologic Response to Treatment
Pathologic response includes pathologic complete response (pCR) or major pathologic responses (MPR). Pathologic response will be evaluated in patients who receive at least one dose of study drug and receive surgery.
Time frame: Up to 2 months
Objective Response Rate (ORR) at 8 Weeks Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1).
Objective response rate (ORR) is defined as the number of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1at 8 weeks. CR = Disappearance af all target lesions, PR = \>30% decrease in the sum of diameters of target lesions. Participants who discontinue due to toxicity or clinical progression prior to post-baseline tumor assesment will be considered as non-responders. Participants who discontinue for other reasons prior to their first dose of study drug will not be included in the analysis.
Time frame: 8 weeks
Overall Survival (OS) Rate at 12 Months
OS rate is defined as the proportion of patients who are alive at 12 months. Estimation based on the Kaplan-Meier curve.
Time frame: 12 months
Overall Survival (OS) Rate at 18 Months
OS rate is defined as the proportion of patients who are alive at 18 months. Estimation based on the Kaplan-Meier curve.
Time frame: 18 months
Overall Survival (OS) at 3 Years
OS rate is defined as the proportion of patients who are alive at 3 years. Estimation based on the Kaplan-Meier curve.
Time frame: 3 years
Overall Survival (OS) at 5 Years
OS rate is defined as the proportion of patients who are alive at 12 months. Estimation based on the Kaplan-Meier curve.
Time frame: 5 years
Disease Free Survival (DFS) Rate at 12 Months
The 12 months DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 12 months from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.
Time frame: 12 months
Disease Free Survival (DFS) at 18 Months
The 18 months DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 18 months from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.
Time frame: 18 months
Disease Free Survival (DFS) at 3 Years
The 3 years DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 3 years from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.
Time frame: 3 years
Disease Free Survival (DFS) at 5 Years
The 5 years DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 5 years from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.
Time frame: 5 years
Overall Survival (OS)
Median OS will be measured from date of randomization or eligibility confirmation until death or end of follow-up. OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis. Estimation based on the Kaplan-Meier curve.
Time frame: 6 years
Disease Free Survival (DFS)
Median DFS is defined as the duration of time from date of randomization or eligibility confirmation to the date of disease progression precluding surgery, disease progression or recurrence at or after surgery, or death, whichever occurs first. Patients will be censored at date of last scan, unless they developed a second, unrelated primary tumor, in which they will be censored at the last scan prior to cancer-directed therapy for the second tumor. Estimation based on the Kaplan-Meier curve.
Time frame: Up to 57 months
| Milestone | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Started | 16 | 15 |
| Completed | 15 | 15 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Number of patients that experienced a treatment-related adverse event that precludes continuing on to surgery within 60 days of the last dose of neoadjuvant treatment. Individuals who do not go on to receive surgery due to other causes (e.g. progressive disease, patient refusal) will not be counted as feasibility failures.
| Participants | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Number of Patients Precluded From Surgery | 0 | 0 |
When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject.
| Participants | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Event (AE) | 4 | 4 |
Number of evaluable participants who obtain R0 resection. R0 resection rate will be estimated among the patients who receive at least one dose of neoadjuvant treatment and went to surgery. R0 resection is defined by a microscopically margin-negative resection, in which no tumor (gross or microscopic) remains in the primary tumor bed.
| Participants | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Number of Participants Who Obtain R0 Resection | 13 | 11 |
Pathologic response includes pathologic complete response (pCR) or major pathologic responses (MPR). Pathologic response will be evaluated in patients who receive at least one dose of study drug and receive surgery.
| Participants | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Number of Evaluable Patients With Pathologic Response to Treatment | 3 | 4 |
Objective response rate (ORR) is defined as the number of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1at 8 weeks. CR = Disappearance af all target lesions, PR = \>30% decrease in the sum of diameters of target lesions. Participants who discontinue due to toxicity or clinical progression prior to post-baseline tumor assesment will be considered as non-responders. Participants who discontinue for other reasons prior to their first dose of study drug will not be included in the analysis.
| Participants | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Objective Response Rate (ORR) at 8 Weeks Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1). | 2 | 3 |
OS rate is defined as the proportion of patients who are alive at 12 months. Estimation based on the Kaplan-Meier curve.
| Percentage of participants | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Overall Survival (OS) Rate at 12 Months | 86.7 (71.1 to 100) | 93.3 (81.5 to 100) |
OS rate is defined as the proportion of patients who are alive at 18 months. Estimation based on the Kaplan-Meier curve.
| Percentage of participants | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Overall Survival (OS) Rate at 18 Months | 72 (51.9 to 99.8) | 86.2 (70.0 to 100) |
OS rate is defined as the proportion of patients who are alive at 3 years. Estimation based on the Kaplan-Meier curve.
| Percentage of participants | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Overall Survival (OS) at 3 Years | 53.3 (31.2 to 91.2) | 86.2 (70.0 to 100) |
OS rate is defined as the proportion of patients who are alive at 12 months. Estimation based on the Kaplan-Meier curve.
Results for this outcome have not been posted.
The 12 months DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 12 months from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.
| Percentage of participants | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Disease Free Survival (DFS) Rate at 12 Months | 75 (54.1 to 100) | 100 (100 to 100) |
The 18 months DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 18 months from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.
| Percentage of participants | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Disease Free Survival (DFS) at 18 Months | 75.0 (54.1 to 100) | 90.0 (73.2 to 100) |
The 3 years DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 3 years from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.
| Percentage of participants | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Disease Free Survival (DFS) at 3 Years | 64.3 (41.2 to 100) | 75 (49.6 to 100) |
The 5 years DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 5 years from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.
Results for this outcome have not been posted.
Median OS will be measured from date of randomization or eligibility confirmation until death or end of follow-up. OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis. Estimation based on the Kaplan-Meier curve.
Results for this outcome have not been posted.
Median DFS is defined as the duration of time from date of randomization or eligibility confirmation to the date of disease progression precluding surgery, disease progression or recurrence at or after surgery, or death, whichever occurs first. Patients will be censored at date of last scan, unless they developed a second, unrelated primary tumor, in which they will be censored at the last scan prior to cancer-directed therapy for the second tumor. Estimation based on the Kaplan-Meier curve.
| Months | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Disease Free Survival (DFS) | 36.49 (18.18 to NA) | NA (26.20 to NA) |
Collected over Serious and Other (Not Including Serious) Adverse Events were evaluated from start of treatment up to 15 months. All-cause mortality was evaluated from start of treatment up to 59 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A - Nivolumab | 6/15 (40%) | 3/15 (20%) | 14/15 (93.3%) |
| Arm B - Nivolumab and Relatlimab | 2/15 (13.3%) | 2/15 (13.3%) | 15/15 (100%) |
| Event | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 1/15 | 0/15 |
| ColitisGastrointestinal disorders | 0/15 | 1/15 |
| DysphagiaGastrointestinal disorders | 1/15 | 0/15 |
| FractureInjury, poisoning and procedural complications | 1/15 | 0/15 |
| Generalized edemaGeneral disorders | 1/15 | 0/15 |
| MyocarditisCardiac disorders | 0/15 | 1/15 |
| MyositisMusculoskeletal and connective tissue disorders | 0/15 | 1/15 |
| SyncopeNervous system disorders | 1/15 | 0/15 |
| Event | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab |
|---|---|---|
| Weight lossInvestigations | 8/15 | 8/15 |
| HypothyroidismEndocrine disorders | 0/15 | 5/15 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 1/15 | 5/15 |
| Back painMusculoskeletal and connective tissue disorders | 2/15 | 4/15 |
| Dry mouthGastrointestinal disorders | 0/15 | 4/15 |
| FatigueGeneral disorders | 4/15 | 4/15 |
| HypertensionVascular disorders | 4/15 | 2/15 |
| HyperthyroidismEndocrine disorders | 0/15 | 4/15 |
| Abdominal painGastrointestinal disorders | 3/15 | 3/15 |
| AnorexiaMetabolism and nutrition disorders | 3/15 | 3/15 |
| Age, Categorical(Participants) | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 9 | 12 |
| >=65 years | 12 | 6 | 18 |
| Sex: Female, Male(Participants) | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab | Total |
|---|---|---|---|
| Female | 5 | 6 | 11 |
| Male | 10 | 9 | 19 |
| Race (NIH/OMB)(Participants) | Arm A - Nivolumab | Arm B - Nivolumab and Relatlimab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 1 | 7 |
| White | 7 | 12 | 19 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2021 to primary completion in Sep 2025, 51 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 147 non-industry phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 80. This study's 51 months is close to that.
Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins →